Lymphatic system

NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer

Retrieved on: 
Monday, September 12, 2022
Lymph, Breast, Policy, Blood, Infection, Patient, National Comprehensive Cancer Network, Strathcona County, Research, CAR, COVID-19, Lymphatic system, Incidence, Person, Bone marrow, Doctor of Philosophy, Journal of the National Comprehensive Cancer Network, Skin, Spleen, NCCN, Stomach, Decision-making, Robert H. Lurie Comprehensive Cancer Center, Lymphoma, Health, Memorial Sloan Kettering Cancer Center, Feinberg School of Medicine, Twitter, Prostate, Immunotherapy, Cancer, Pathology, Diagnosis, PMID, Caregiver, Lung, Awareness, Education, Toxicity, Vaccine, Pharmaceutical industry, Medical device, Medicine, Amazon, MD, B-cell lymphoma

PLYMOUTH MEETING, Pa., Sept. 12, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.

Key Points: 
  • A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.
  • The patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN's library of NCCN Guidelines for Patients , published through funding from the NCCN Foundation and available online free of charge.
  • NCCN Guidelines for Patients are available for free online at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App .
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

Retrieved on: 
Monday, September 12, 2022
Risk, TSX, Lymphatic system, FDA, Company, Compliance, G1, Hematology, MDS, Patient, Clinical trial, Exchange, Lymphoid leukemia, Acute myeloid leukemia, Nasdaq, Toxic leukoencephalopathy, NASDAQ, SAN, AML, GLOBE, Absorption, Plasma, Pharmaceutical industry, Vaccine, G3

SAN DIEGO and TORONTO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the G3 formulation of luxeptinib, designed for rapid and efficient absorption, demonstrates approximately an 18-fold improvement in oral bioavailability relative to the original G1 formulation, and that Aptose plans to move forward with the development of the G3 formulation of luxeptinib to determine if it can achieve desired exposures and deliver clinical responses while continuing to demonstrate a favorable safety profile.

Key Points: 
  • The new G3 formulation, designed for more efficient absorption that could lead to greater accumulation and higher steady-state exposure levels, now has been tested as a single dose in 15 patients in the ongoing clinical trials.
  • Initial computational modeling of the pharmacokinetic (PK) properties of G3 predicts that plasma steady-state exposure achieved with continuous dosing of 50 mg of G3 (every 12 hours, Q12h) is equivalent to that of 900 mg of G1 Q12h, representing up to an 18-fold improvement in bioavailability with G3.
  • The G3 formulation of luxeptinib has shown a significant improvement in bioavailability and the potential for greater absorption, and we are eager to move forward with continuous dosing in our AML trial, said William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer of Aptose.
  • The original G1 formulation of luxeptinib delivered a complete remission (CR) in one AML patient that safely achieved a particularly high plasma steady-state exposure, and we are hopeful the new G3 formulation will enable patients to receive greater exposures and benefit from treatment with Lux.

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Retrieved on: 
Monday, September 12, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Hospital, Risk, Therapy, Safety, Haematopoietic system, Infection, COVID-19, Transplant, Twitter, Lymphatic system, Global, FDA, HSCT, Hematology, 2009 Davis Cup, Phenotype, LinkedIn, Functional Assessment of Cancer Therapy - General (FACT-G), Quality of life, Breakthrough therapy, Private Securities Litigation Reform Act, Outcome, PDUFA, U.S. Securities and Exchange Commission, NK, Patient, Facebook, Immunotherapy, Technology, Instagram, Cell, Bone marrow, B cell, RTE, UCB, Security (finance), Graft-versus-host disease, BLA, Diversity, SEC, Mortality, NAM, Trial of the century, Pharmaceutical industry, Medicine, Dentistry, EU, Black

The data suggest meaningfully greater preservation or improvement of important HRQL domains in patients treated with omidubicel compared to UCB.

Key Points: 
  • The data suggest meaningfully greater preservation or improvement of important HRQL domains in patients treated with omidubicel compared to UCB.
  • Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

Retrieved on: 
Monday, September 12, 2022
Securities Exchange Act of 1934, Safety, COVID-19, Lymphatic system, IND, HLA, Company, Growth, Private Securities Litigation Reform Act, Therapy, U.S. Securities and Exchange Commission, Patient, TCR, Hand, Clinical trial, Cancer, Prime rate, Hematopoietic stem cell transplantation, CEO, Analysis, Financial condition report, Result, Solution, Goal, Nasdaq, Annual report, Research, Security (finance), 23rd Street station (IND Eighth Avenue Line), GLOBE, Pharmaceutical industry

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has entered into a debt financing facility for up to $60 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.  

Key Points: 
  • TScan drew $30 million from K2HV upon closing of the loan agreement.
  • The first tranche of the loan is convertible at the option of K2HV into common shares of TScan at a conversion price of approximately $4.785 per share.
  • K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries.
  • Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Leukemia Therapeutics Global Market Report 2022: A $20+ Billion Market in 2026 - Long-term Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022
Pharmaceutical, Health, Oncology, GlaxoSmithKline, Therapy, Chronic lymphocytic leukemia, Immunotherapy, Lupin Limited, Texas Homecare, Prevalence, Exelixis, Asia-Pacific, Takeda Pharmaceutical Company, Organization, Acquisition, National, Growth, Leukemia, MorphoSys, Industry, Patient, Cancer, Acute leukemia, Bone marrow, Acute myeloid leukemia, Amgen, Pfizer, Bristol Myers Squibb, AbbVie, Celgene, Lymphatic system, Immune system, Hospital, National Cancer Institute, Medical device, Pharmaceutical industry, Oil, Trillium

The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities (organizations, sole traders, and partnerships) that are used for the treatment of leukemia.

Key Points: 
  • The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities (organizations, sole traders, and partnerships) that are used for the treatment of leukemia.
  • The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The leukemia therapeutics market research report is one of a series of new reports that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry.
  • Global Leukemia Therapeutics Market, Segmentation By Type Of Leukemia, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Cytovia Therapeutics Presents New Preclinical Data for Its GPC3 Flex-NK™ Cell Engager Antibody in Combination With Natural Killer Cells at ESMO 2022 in Paris

Retrieved on: 
Monday, September 12, 2022
Adult, GPC3, Blood, TALEN, Hepatitis B, Patient, HCC, Technology, Oncology, AFP, TKI, Research, Animal, Disease, Death, ESMO, Cornerstone, Fatty liver disease, Liver cancer, Glioblastoma, Life expectancy, Lymphatic system, UCSF, Survival rate, American Cancer Society, Laboratory, NASH, Neoplasm, Poster, European Society of Gene and Cell Therapy, Partnership, INSERM, NK, CET, Ink, Cytolysis, Incidence, Cellectis, European Society for Medical Oncology, Non-alcoholic fatty liver disease, Therapy, Immunotherapy, Survival, Risk, NAFLD, Cancer, Bell, Cell, Hepatocellular carcinoma, Diagnosis, Multimedia, Placenta, Vaccine, Medical imaging, NCR1

CYT-303 is a multifunctional bispecific NK cell engager built on our Flex-NKTM scaffold, which engages NK cells through NKp46 and targets GPC3 expressed on tumor cells.

Key Points: 
  • CYT-303 is a multifunctional bispecific NK cell engager built on our Flex-NKTM scaffold, which engages NK cells through NKp46 and targets GPC3 expressed on tumor cells.
  • CYT-303 showed dose-dependent HCC tumor growth inhibition in PBNK and iNK cell injected HCC tumor models.
  • CYT-303 treated animals showed significant decreases in blood PBNKs suggesting CYT-303 may facilitate trafficking of these cells from blood to the tumor.
  • The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK technology.

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

Retrieved on: 
Saturday, September 10, 2022
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Time, U.S. Securities and Exchange Commission, Goal, Oncology, Tislelizumab, Adult, ORR, Company, BTK, Sorafenib, European Society for Medical Oncology, ESMO, OS, Safety, Intellectual property, Macrophage, BIRC, Docetaxel, C1-inhibitor, Union, AES, Large-cell lung carcinoma, Incidence, Global health, Private Securities Litigation Reform Act, Antibody, Therapy, PFS, Patient, Death, COVID-19, NSCLC, Novartis, SSE, PD-1, Form 10-Q, Bristol Myers Squibb, Hepatocellular carcinoma, Congress, Technology, Jazz Pharmaceuticals, Immunoglobulin G, Twitter, NASDAQ, Survival, Research, Lymphatic system, Marketing, Dor, RECIST, HCC, PARP, Pharmaceutical industry, Medical imaging, Vaccine, BeiGene

Median progression-free survival (PFS) for tislelizumab versus sorafenib was 2.1 months vs. 3.4 months respectively; HR: 1.11 [95% CI: 0.92, 1.33].

Key Points: 
  • Median progression-free survival (PFS) for tislelizumab versus sorafenib was 2.1 months vs. 3.4 months respectively; HR: 1.11 [95% CI: 0.92, 1.33].
  • AEs leading to death were low across both tislelizumab (4.4%) and sorafenib (5.2%) arm.
  • Were pleased to share the data at ESMO today and to engage with leading oncology researchers about our expansive clinical development program for tislelizumab in solid tumors.
  • More information on the tislelizumab development program, including clinical trials and regulatory submissions, can be found on the Tislelizumab Fact Sheet in our corporate press kit .

Global FLT3 Inhibitors Market Research Report 2022: Focus on Commercialized Therapy & Potential Pipeline Products - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
General Health, Pharmaceutical, Health, Investigational New Drug, Fibroblast growth factor receptor 1, NDA, Allar, Jerusalem, Cancer, Research, Abbreviated New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RCC, Therapy, IND, Benchmarking, AML, Incidence, New Drug Application, Novartis, Food, Renal cell carcinoma, Diagnosis, Acute myeloid leukemia, Investment, Region, Lymphatic system, Classification, FLT3, Daiichi Sankyo, Biology, FDA, CAGR, CRL, Adult, Crenolanib, Country, Name, Endpoint security, Industry, Drug development, Astellas Pharma, Growth, Patient, Pharmaceutical industry, Gilteritinib, Limited

The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The current study aims to assess the global FLT3 inhibitors market by focusing on the marketed and potential pipeline therapies.
  • Increasing investments in the research and development of drug manufacturing are one of the major opportunities in the global FLT3 inhibitors market.
  • The growing interest of the pharmaceutical industry in the therapeutic potential for treating blood cancers with FLT3 positive mutations has been a catalyst for the progress of the global FLT3 inhibitors market.

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

Retrieved on: 
Thursday, September 8, 2022
Health, Medical Devices, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, COVID-19, University, Security (finance), University of California, Hastings College of the Law, Lymphatic system, Corporation, Safety, Geron Corporation, Research, Takeda Oncology, Novo Nordisk, Haas School of Business, Hoffmann-La Roche, Board, Business development, Imetelstat, Genentech, Microdeletion syndrome, U.S. Securities and Exchange Commission, Triple accreditation, Board of directors, Nasdaq, Company, Biotechnology, Law, Risk, Biogen, University of California, Berkeley, Intellectual property, Private Securities Litigation Reform Act, Growth, MDS, Pharmaceutical industry, Management, Sanofi

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022.
  • We enthusiastically welcome him to the Board, said John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer.
  • I am delighted to join Gerons Board at this exciting time, as the company nears top-line results in lower risk MDS in early January 2023, said John F. McDonald.
  • Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Study from The Leukemia & Lymphoma Society Provides New Information on How Blood Cancer Patients Respond to COVID-19 Vaccines

Retrieved on: 
Thursday, September 8, 2022
Leukemia & Lymphoma Society, COVID-19, Public health, Cancer, American Association for Cancer Research, Vaccination, Research, RYE, Pfizer–BioNTech COVID-19 vaccine, Vaccine, Antibody, LLS, Chronic lymphocytic leukemia, Blood, Respiratory system, Leukemia, B cell, Cell, Center, Lymphoma, Severe acute respiratory syndrome coronavirus 2, Human, Lymphatic system, Patient, Immune system, Hodgkin lymphoma, Korea Disease Control and Prevention Agency, ET, Association, RNA transfection, Multiple myeloma, CDC, Omicron, American Association, Pharmaceutical industry

RYE BROOK, N.Y., Sept. 8, 2022 /PRNewswire/ -- A new study from The Leukemia & Lymphoma Society (LLS), published in Blood Cancer Discovery, a journal of the American Association for Cancer Research (https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230...), reports that blood cancer patients who do not produce detectable antibodies after COVID-19 vaccination may have another form of protection: T-cells that are designed to attack the COVID-19 virus. Findings from the LLS National Patient Registry showed that 45% of blood cancer patients who had no detectable antibodies after two Moderna or Pfizer/BioNtech vaccines generated T-cells.

Key Points: 
  • Findings from the LLS National Patient Registry showed that 45% of blood cancer patients who had no detectable antibodies after two Moderna or Pfizer/BioNtech vaccines generated T-cells.
  • "As LLS continues to contribute important scientific information about how COVID-19 vaccines work, our message to blood cancer patients remains the same: get vaccinated, act unvaccinated," says study author Lee Greenberger, Ph.D., Chief Scientific Officer of LLS.
  • The new paper also reports on the effect of a third primary COVID-19 vaccine dose on antibody levels in blood cancer patients.
  • LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.